The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy

American Heart Journal

Volumn 142, Issue 2, 2001, Pages 211-217

  Alpert, Joseph S ^f   De Lemos, James A ^c   Dyke, Christopher K ^a   Califf, Robert M ^b   Bilheimer, David ^d   Braunwald, Eugene ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; SIMVASTATIN; TIROFIBAN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION;

EID: 0034901024     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.116959     Document Type: Article

References (24)

1. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
2. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina non-Q-wave myocardial infarction
3. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
4. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
5. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes
6. Anti-thrombotic combination using tirofiban and enoxaparin: The Acute II Study
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
8. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
10. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium)
11. Non-lipid-related effects of statins
12. Four-year survival of patients with acute coronary syndromes without ST-segment elevation and prognostic significance of 0.5-mm ST-segment depression
13. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: Results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in myocardial ischemia
14. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina)
15. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease: The Heart and Estrogen/Progestin Replacement Study (HERS)
16. EUROASIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results
17. Swedish Register of Cardiac Intensive Care. Early statin treatment following acute myocardial infarction and 1-year survival
18. Hormone replacement therapy and cardiovascular disease
19. The HERS trial results: Paradigms lost? Heart and Estrogen/progestin Replacement Study
20. Design of a cost-effectiveness study within a randomized trial: The LIPID Trial for secondary prevention of IHD. Long-term intervention with pravastatin in ischemic heart disease
21. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease